Fig. 4: Opposing roles of wild-type and mutant p53 in CK2-mediated HMGA1 secretion.
A Immunoblot of CK2-phosphorylated substrate (pCK2 substrate) 48 h after AsPC-1 cells were transiently transfected with MOCK, TP53WT or TP53R273H. Bar charts depict the average signal intensity (A.I.) in a.u. of phospho-CK2 substrate versus Vinculin. Data plotted are mean of three independent experiments +/- SD. (One-way ANOVA). * p < 0.05. B Immunoblot of pCK2 substrate 24 h after 1 µM GEM treatment of PaCa3 cells. Bar charts depict the A.I. of pCK2 substrate versus Vinculin (a.u.). Data are presented as the mean of three independent experiments +/- SD. (Unpaired t-test). C Immunoblot of pCK2 substrate 24 h after 1 µM GEM treatment of PANC-1 cells. Bar charts depict the A.I. of pCK2 substrate versus Vinculin (a.u.). Data plotted are mean of three independent experiments ± SD. (Unpaired t-test). *p < 0.05. D Immunoblot of HMGA1 protein in PANC-1 and TP53 KO PANC-1 secretome after treatment with 1 µM GEM. E Immunoblot of HMGA1 in PANC-1 cell secretome after 1 µM GEM and 50 µM APR-246 treatments. F Immunoblot of p-p53, p53 and HMGA1 proteins in PANC-1 cells treated with or without 1 µM GEM and with or without 50 µM APR-246. G Immunoblot of HMGA1 in PANC-1 cell secretome after 1 µM GEM and 10 µM or 50 µM TBB treatments. H Immunoblot of HMGA1 proteins in PANC-1 cells treated with or without 1 µM GEM and with or without 10 or 50 µM TBB.
